A study published in the journal Addiction has found that existing harm reduction frameworks, developed primarily for drugs such as heroin or methamphetamine, do not adequately address the specific risks associated with anabolic-androgenic steroids (AAS).
New research calls for the adaptation of public health strategies tailored to the unique patterns of steroid use.
Key Differences in Risk Profiles
The study identifies several fundamental differences between AAS and other controlled substances that render traditional harm reduction models less effective.
AAS harms typically develop over long-term use, affecting organ systems such as the heart, liver, and kidneys. This contrasts sharply with the acute risks, such as overdose, associated with other drugs.
Furthermore, AAS use is described as structured, goal-driven, and often cycle-based, with users frequently viewing their behavior as related to health or performance enhancement rather than as "drug use."
Findings on Product Purity and Safety
Research conducted through the ROIDCheck project in Queensland tested 212 illegal steroid samples. The findings indicated that fewer than 10% of the samples contained the expected substance at the stated dose.
The study also notes that oral steroids, which are sometimes perceived as safer than injectables, carry risks of liver toxicity and exhibit high rates of mislabeling or contamination.
Recommendations for Revised Approaches
The study proposes several adjustments to harm reduction strategies:
- Expand initiatives beyond injection-focused approaches to include comprehensive education on dosing, cycling practices, and long-term health monitoring.
- Train health professionals to recognize and respond to the distinct patterns of AAS use.
- Integrate digital environments and online communities—where many users obtain information—into risk communication strategies.
Context and Legal Status
Anabolic-androgenic steroids are illegal in Australia without a prescription and are used primarily for performance or image enhancement.
"Recognizing the diversity of drug use, including drugs used for enhancement, represents a significant next frontier for public health."
— Dr. Timothy Piatkowski, University of Queensland